Potent Antimalarial 2‑Pyrazolyl Quinolone bc1 (Qi) Inhibitors with Improved Drug-like Properties
journal contributionposted on 19.10.2018, 00:00 by W. David Hong, Suet C. Leung, Kangsa Amporndanai, Jill Davies, Richard S. Priestley, Gemma L. Nixon, Neil G. Berry, S. Samar Hasnain, Svetlana Antonyuk, Stephen A. Ward, Giancarlo A. Biagini, Paul M. O’Neill
A series of 2-pyrazolyl quinolones has been designed and synthesized in 5–7 steps to optimize for both in vitro antimalarial potency and various in vitro drug metabolism and pharmacokinetics (DMPK) features. The most potent compounds display no cross-resistance with multidrug resistant parasite strains (W2) compared to drug sensitive strains (3D7), with IC50 (concentration of drug required to achieve half maximal growth suppression) values in the range of 15–33 nM. Furthermore, members of the series retain moderate activity against the atovaquone-resistant parasite isolate (TM90C2B). The described 2-pyrazoyl series displays improved DMPK properties, including improved aqueous solubility compared to previously reported quinolone series and acceptable safety margin through in vitro cytotoxicity assessment. The 2-pyrazolyl quinolones are believed to bind to the ubiquinone-reducing Qi site of the parasite bc1 complex, which is supported by crystallographic studies of bovine cytochrome bc1 complex.
Read the peer-reviewed publication
ubiquinone-reducing Q i sitecytotoxicity assessment2- pyrazolyl quinolonesdrug metabolismDrug-like Propertiesparasite bc 12- pyrazoyl series displaysparasite strainsDMPK propertiesatovaquone-resistant parasitegrowth suppressionQ iquinolone seriesIC 50safety marginTM 90Ccompounds displayantimalarial potencycytochrome bc 1